Encorafenib & Binimetinib
from OncoPharm Hosted by John Bossaer
The newly FDA-approved BRAF & MEK inhibitors are discussed, along with their possible clinical relevance and some notable differences compared to previously available BRAF & MEK inhibitors.
Embed this episode
No transcript yet.
Frequently asked questions
How long is this episode of OncoPharm?
This episode is 17 minutes long.
When was this OncoPharm episode published?
This episode was published on June 28, 2018.
Can I download this OncoPharm episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.